Bio-Path Holdings, Inc. Form 8-K Filing Summary

This Form 8-K filing by Bio-Path Holdings, Inc. details several significant events. On April 30, 2026, the company raised $13,983 through the sale of 466,100 common shares under a Tier 1 Regulation A offering. A subsequent sale on May 13, 2026, raised an additional $14,676 from 489,200 common shares. The company has the potential to raise further capital under this offering. A new class of Series B Preferred stock was approved on July 14, 2026, with 5,000,000 authorized shares, convertible into common shares. The company is undergoing a strategic turnaround, exploring options such as restarting drug trials, licensing intellectual property, pivoting to blockchain technology, and strategic acquisitions. Key developments include an agreement with UT MD Anderson Cancer Center to restart Phase 2 trials for AML, subject to payment of outstanding balances. Bio-Path also opened a business account with Coinbase to manage a digital asset treasury, intending to allocate up to 50% of raised capital to crypto opportunities. The company engaged Farrington Capital Group to find a strategic investor or partner for its biotechnology assets and intellectual property. Additionally, Bio-Path issued Series B Preferred shares to acquire a majority stake in Himalaya Technologies, Inc., which operates a crypto social site and trading platform. The CEO also received Series B Preferred shares for a software platform to enhance the crypto social site. Himalaya Technologies terminated a development agreement and canceled Series B Preferred shares. Richard Fetyko, CEO of altFINS, joined the Advisory Board, with plans for a partnership and cross-investment involving altFINS' AI-driven capabilities and Bio-Path's digital asset treasury.